The use of epsilon-aminocaproic acid (EACA) and other anti-fibrinolytic agents has been explored to prevent re-hemorrhage following subarachnoid hemorrhage (SAH) secondary to aneurysmal rupture. One reported complication includes increased rates of hydrocephalus (HCP) due to EACA administration. Herein, we present a single-institution case-control study investigating the relationship between EACA administration and the development of shunt-dependent HCP. All patients were managed by a single neurosurgeon at the University of Alabama at Birmingham (UAB) Medical Center who treated SAH patients with EACA. A power analysis was performed to determine the sample size, and 57 patients who required a ventriculoperitoneal shunt (VPS) for management of obstructive hydrocephalus after failing an external ventricular drain wean protocol were selected. Control patients with initial obstructive hydrocephalus who did not require VPS were matched by demographic factors. The overall rate of VPS placement was 44%; the odds ratio of VPS placement after treatment with EACA was 0.63. The presence of intraventricular hemorrhage or a poor clinical exam on presentation was closely associated with eventual placement of a VPS, with the odds ratio for a Fisher CT grade 4 hemorrhage being 13.89 and a clinical exam corresponding to a Hunt and Hess score of III and IV being 17.18 and 11.00, respectively. The administration of EACA does not appear to increase the incidence of shunt-dependent HCP following SAH and may therefore be employed if clinically needed. Intraventricular hemorrhage or a poor clinical exam on presentation does appear to increase the incidence of shunt-dependent HCP following SAH.
Introduction
Re-hemorrhage is a significant complication following aneurysmal subarachnoid hemorrhage (SAH) with mortality following re-hemorrhage as high as 74% in some reported series [1, 2] . Anti-fibrinolytic agents have been used to prevent re-hemorrhage following SAH [3] .
Without anti-fibrinolytic treatment, the rate of rehemorrhage has been found to be as high as 19 .3% in the first 24 h following aneurysmal rupture [4] , whereas anti-fibrinolytic treatment has been shown to reduce the rate of re-hemorrhage [5] [6] [7] , in some instances to as low as 2.4% prior to securement of the aneurysm [8] .
Long-term use of anti-fibrinolytic agents (i.e., for a week or more) fell out of favor due to complications related to cerebral ischemia [3, 9] , although some studies have suggested that short-term use of EACA prior to early treatment of ruptured aneurysms is protective against re-hemorrhage and does not carry the same risk of cerebral ischemia [5, 8, 10] .
Epsilon-aminocaproic acid (EACA) is an anti-fibrinolytic agent that is commonly used following SAH. EACA is a lysine analog that competitively inhibits the conversion of plasminogen to plasmin. Unfortunately, two frequently cited studies have reported that use of EACA increases the rate of post-SAH hydrocephalus (HCP) [10, 11] .
Treatment with EACA has been suspected to be a risk factor for HCP after SAH in our institutional cohort as well [5] , and because of this, one cerebrovascular surgeon at our center stopped using EACA to treat SAH patients prior to early treatment of the ruptured aneurysm. This allowed us to design this case-control study using the patients from this one surgeon to determine if EACA administration was indeed associated with the development of chronic HCP requiring placement of a ventriculoperitoneal shunt (VPS).
Methods

Study Design
This study population includes patients admitted to the Neurological Surgery service with a diagnosis of aneurysmal SAH under the care of a single cerebrovascular neurosurgeon at the University of Alabama at Birmingham (UAB). A power analysis was conducted to determine the sample size needed, and the effect size for a twosample χ 2 proportion test with unequal numbers was computed based on published results reporting a 20% shunt rate in patients without EACA treatment [12] and a 43% shunt rate in patients who received EACA [11] . The power calculation, based on a one-sided test since the a priori hypothesis was that EACA increased the occurrence of HCP, indicated that with a significance level of 0.05, this study would provide 88% power to detect a statistically significant difference between the two groups with regard to EACA treatment. Statistical power analysis and sample size determination were done with nQuery Advisor version 7.0 (Statistical Solutions, Cork, Ireland).
Based on the power analysis, 57 patients who required a VPS were identified and labeled as the cohort of interest. An additional 72 patients were identified as controls. The controls were matched to the cohort with regard to age, gender, ethnicity, and smoking status. All patients were identified from the aneurysm database maintained at our institution. Demographic and clinical information was also derived from 
Clinical Management
All patients admitted prior to February 1, 2011, received EACA as part of their treatment plan. Those patients receiving EACAwere treated with a standard protocol in which they were given a 5-g intravenous loading dose on admission to the neurosurgical intensive care unit. A continuous infusion of 1 g/h was then given until immediately before the ruptured aneurysm was treated with either surgery or coiling. Beginning on February 1, 2011, patients admitted to the Neurological Surgery service did not receive EACA or any other anti-fibrinolytic agent. Radiographic workup on admission included computed tomography (CT) angiography or catheter angiography to identify the ruptured aneurysm. Once the radiographic workup was complete, patients underwent treatment of the ruptured aneurysm with either surgery or coil embolization when medically stable. All patients received standard neurocritical care measures during their hospitalization, including adequate hydration, nutritional support, neurological monitoring, and nimodipine. Any patient with a neurological change underwent a workup including an emergent head CT scan and electrolyte measurements and, if indicated, an angiogram to investigate for vasospasm. Patients were considered to have symptomatic vasospasm if neurological signs or symptoms associated with vasospasm developed; other causes of neurological change (such as re-hemorrhage or HCP) were excluded, and additional radiographic studies (such as CT angiography or angiography) supported the diagnosis of vasospasm. Patients with symptomatic HCP were treated initially with ventriculostomy. The external ventricular drain wean protocol was initiated on patients once their clinical exam and/or transcranial Doppler (TCD) trends (particularly important in patients who remained intubated and whose clinical exam was difficult to follow) were reassuring as to eliminate confounding effects of symptomatic vasospasm as much as possible. Ventriculostomies were weaned by sequentially raising the pop-off level by 5-mmHg increments and observing the patient for headache, lethargy, or other signs of increased intracranial pressure over~5-10 days after treatment of the aneurysm. All patients who tolerated having the pop-off at 20 mmHg then had the ventriculostomy clamped and underwent a CT scan to assess for worsening ventriculomegaly. Patients with worsening ventriculomegaly or symptoms attributable to HCP such as somnolence or obtundation, headache, nausea, vomiting, increased intracranial pressure, or leakage around the drain site during the weaning process underwent surgery for placement of a VPS.
Data Analyses
Demographics (gender, race, smoking and hypertension status) and clinical characteristics including Fisher's CT grade, the Hunt and Hess scale, EACA utilization, and preoperative and postoperative drainage were summarized using frequency counts and percentages. Chi-square tests (or Fisher's exact tests when assumptions were not met) were used to assess statistical significance of differences according to HCP development. Age was presented as means and standard deviations with Student's t test used to compare differences based on shunt status. Logistic regression, with the development of HCP as the outcome variable, was used to identify independent associations with clinical examination predictors. Statistical significance was defined as p < 0.05. Descriptive and inferential statistical analyses were performed using SAS version 9.3 (SAS Institute, Inc., Cary, NC).
Results
Baseline characteristics of the study subjects are presented in Table 1 . Out of the 129 total patients studied, 57 (44.2%) developed chronic HCP and underwent placement of a VPS. EACA was more commonly found in the non-shunted control group than in the case group, with EACA exposure having an odds ratio of 0.63 (95% CI 0.31-1.26) for the development of shunt-dependent HCP (Table 2) . Of the shunted patients, 25 (43.9%) received EACA prior to treatment (Table 3 ). There was no significant difference between this rate and that found in the control group in which 55.6% (40/72) received EACA.
Critically, the patients' clinical examination and radiographic presentation upon admission, as indicated by the admission Hunt and Hess scale and Fisher's CT grade, were associated with the development of chronic HCP. In univariate analysis, the presence of intraventricular hemorrhage was found to have an odds ratio of 13.89 (95% CI 0.56-343.44) for developing shunt-dependent HCP (Table 2) . Intraventricular hemorrhage (Fisher's CT grade 4 SAH) was present in 38 of 57 (66.7%) of patients who underwent VPS compared with 30 of 72 (41.7%) of non-shunted patients, a statistically significant finding (p = 0.01).
The strongest predictor of development of HCP was the clinical examination on presentation. Patients who presented with a Hunt and Hess score of III or IV were more likely to require VPS than other patients. The Hunt and Hess III and IV patients had odds ratios of 17.18 (95% CI 1.89-156.54) and 11.00 (95% CI 1.01-109.67), respectively, for the development of shunt-dependent HCP (Table 2) . Patients with this clinical presentation accounted for 66.7% (38/57) of the shunted patients and only 25% (18/72) of the non-shunted patients. Conversely, patients with a better presentation (Hunt and Hess I and II) accounted for 31.6% (18/57) of the VPS patients and 65% (47/72) of the controls (Table 4) .
Patients who required ventriculostomy for treatment of acute HCP were also more likely to develop chronic HCP. Patients who went on to require VPS were treated with a ventriculostomy in the preoperative period in 47.4% (25/57) of cases and in 77% (44/57) of the time postoperatively. This compares with 23.6% (17/72) preoperatively and 31.9% (23/ 72) postoperatively for the control group (Table 4) .
Discussion
HCP is a well-recognized consequence of aneurysmal SAH [12] [13] [14] [15] . The development of HCP is multifactorial [16, 17] , but outflow obstruction at the level of the arachnoid granulations has been implicated as the driving force behind the development of raised intracranial pressure following SAH [13, [18] [19] [20] . Many studies have sought to identify factors that contribute to the development of shunt-dependent HCP following SAH, and several have implicated antifibrinolytic agents in the development of HCP [3, 11] .
The use of EACA and other anti-fibrinolytic agents for the prevention of aneurysmal re-hemorrhage is well established [3] . This practice has been shown to reduce the incidence of rerupture and the morbidity and mortality associated with such events [21] . The practice of treating with EACA or a similar agent for a prolonged period of time (> 7 days) prior to definitive treatment of the aneurysm has largely fallen out of favor because of cerebral ischemia induced by the prolonged exposure to EACA [3, 9, 22] . It has even been suggested that short-term use of EACA may significantly increase the risk of systemic thromboembolic complications [23] . Still, several studies and review articles indicate that limited, short-term use of EACA and similar agents prior to early definitive treatment of the ruptured aneurysm is a safe and effective measure to prevent early re-hemorrhage [5, 8, 10, 24] . A study of patients with angiographically negative subarachnoid hemorrhage, historically known to be much less likely to experience re-hemorrhage, also did not find evidence that short-term use EACA correlated with an increase in clinically adverse outcomes [25] . A recent study combining data from two centers in the Netherlands where tranexamic acid (TXA) is the anti-fibrinolytic drug employed found neither a decreased rate of hemorrhage nor an increased rate of complications related to its use, although mortality was found to be significantly lower in the patient population in which it was administered in the short term [26] .
A Cochrane Collaboration review article dedicated to the subject of the use of anti-fibrinolytic agents following aneurysmal SAH shed light on important findings related to this topic [22] . The primary outcome measure of interest in this review was a poor outcome as defined by the Glasgow Outcome Scale or modified Rankin Scale following a minimum of 3-month follow-up after aneurysmal hemorrhage. A secondary outcome measure of interest was the development of HCP. The review identified five studies that investigated the relationship between confirmed HCP and the administration of an anti-fibrinolytic agent [9, [27] [28] [29] . This review found no significant relationship between the administration of an antifibrinolytic agent and the development of HCP (RR 1.14, 95% CI 0.86-1.51). Of note, all of the studies cited in the Cochrane review were investigating long-term use of anti-fibrinolytic agents, which is in contrast to our study in which short-term use of an anti-fibrinolytic agent was employed.
The results of our study serve to refute the notion that EACA causes an increased rate of HCP when used for a short duration of time. Rather, we found a correlation between administration of EACA and a lower rate of shunting. Factors that were found to be related to an increased rate of HCP were [12, 13, 18, [30] [31] [32] [33] .
One area in which our study is an outlier is in the rate of placement of a VPS. Patients included in this study underwent placement of a VPS in 44.2% of cases. This is consistent with previous reports from our institution [5] , but significantly higher than other reported series [10, 13, 18, 20, 30, 32] . Our length of time from aneurysmal rupture to VPS insertion is 11.4 days (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , which is much shorter than other studies reported in the literature. Dehdashti reports a mean time to VPS insertion of 36 days [18] ; Kosteljanetz reports 42 days [20] . The two longest durations from bleed to VPS insertion were in patients with Hunt and Hess V examinations upon presentation. Patients with Hunt and Hess V examinations are much sicker and require more life-sustaining treatment than their counterparts. The necessity to watch these patients in the ICU for prolonged periods of time may lead to more extended ventriculostomy weaning and a lower shunt rate. This practice of shorter shunt weaning than others reported in the literature may also lead to the higher rate of VPS insertion in our study (44.2%) than in others reported in the literature (range 15.5-21.4%) [13, 18, 30, 32] .
A number of studies have shown that the presence of intraventricular hemorrhage correlates with the development of HCP [12, 31, [33] [34] [35] [36] . Similarly, the severity of SAH also correlates with the rate of both acute HCP [33] and shuntdependent HCP [12, 31, 32] . The fact that the present study also identified these factors to be significant risk factors for HCP, and yet did not find EACA administration to be significant risk factors, lends weight to the conclusion that EACA may not be a significant risk factor for shunt-dependent HCP.
Conclusion
Previous studies have reported an association between antifibrinolytic therapy and HCP. This study did not find that shortterm EACA administration leads to higher rates of HCP. Factors that were related to the development of HCP were the presence of intraventricular hemorrhage or a thick cisternal clot as evidenced by a Fisher CT grade of 3 or 4, or a poor neurologic examination on presentation as evidenced by a Hunt and Hess scale of III or IV. The prior literature on the subject of the effect of anti-fibrinolytic agents on the development of post-SAH HCP is sparse and gives class III evidence that anti-fibrinolytic agents do not lead to HCP. Our retrospective cohort study represents class II evidence that supports the existing literature; critically, our results suggest that clinicians may safely employ EACA for short durations if deemed necessary to prevent re-hemorrhage prior to definitive management of a ruptured aneurysm.
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